Darusentan

DRUG5 trials

Sponsors

Gilead Sciences

Conditions

Hypertension

Phase 2

A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs

CompletedNCT00364026

Gilead SciencesHypertension

Start: 2004-06-30End: 2005-07-31Updated: 2007-01-18

Phase 3

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

CompletedNCT00330369

Gilead SciencesHypertension

Start: 2006-06-30End: 2009-01-31Updated: 2014-03-18

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

TerminatedNCT00353574

Gilead SciencesHypertension

Start: 2006-09-30End: 2010-04-30Updated: 2014-03-18

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

TerminatedNCT00389675

Gilead SciencesHypertension

Start: 2007-05-31End: 2010-05-31Updated: 2014-01-06

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

CompletedNCT00389779

Gilead SciencesHypertension

Start: 2006-09-30End: 2009-08-31Updated: 2014-03-18

Related Papers

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

2009-09-11233 citations